Page 14 - Angle Plc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

16 April 2021 | 07:54am StockMarketWire.com - Liquid biopsy company Angle said it had won its first pharma services contract worth $1.2 million over 18 months with scope for further contracts from the same customer. The customer would use the company's parsortix system in cancer drug trials for liquid biopsy longitudinal monitoring. The work related to a phase 3 prostate cancer study and two smaller phase I studies. 'The phase I studies, if successful, could progress to larger phase II studies and, if successful, much larger phase III studies,' the company said. 'The services cover the capt...

About ANGLE plc   www.angleplc.com   ANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLE's proven patent protected platforms include a circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.   ANGLE's cell separation technology is called the Parsortix® system, and it enables a liquid biopsy (a simple blood test) to be used to provide the cells of interest to the user in a format suitable for multiple type...

Share this article Share this article ResearchAndMarkets.com's offering. The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding initiatives, patents and companies. The market sizes for liquid biopsy diagnostics are given for 2019, 2020 and 2025 (forecasted). Liquid biopsy is creating a paradigm shift in medicine, and this is opening significant market opportunities. These market segments are particularly promising for the following liquid biopsy applications: noninvasive prenatal screening for average-risk populat...

4 March 2021 | 10:11am StockMarketWire.com - Liquid biopsy company Angle said it was likely that US clearance for Parsortix would occur later than initially expected after the company received a request to supply further information from the US Food and Drug Administration. The company said it was likely clearance would occur in the second half of 2021 rather than the previous guidance of the "earliest prospect of FDA clearance being Q2 CY21". 'Some of the technical information requested necessitates some targeted additional analytical studies,' it added. 'However, these additional an...

About ANGLE plc www.angleplc.com   ANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLE's proven patent protected platforms include a circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.   ANGLE's cell separation technology is called the Parsortix ® system, and it enables a liquid biopsy (a simple blood test) to be used to provide the cells of interest to the user in a format suitable for multip...